Connect with us

Hi, what are you looking for?

Economy

Two Chinese vaccines remained active vs S.Africa variant but effect reduced

BEIJING — Two COVID-19 vaccines from Chinese companies including Sinopharm triggered immunity against a highly transmissible coronavirus variant first found in South Africa, but their effect appeared weaker, a small-sample lab study released on Tuesday showed.

Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.

Twelve serum samples each taken from recipients of two vaccines developed by a subsidiary of China National Pharmaceutical Group (Sinopharm) and a unit of Chongqing Zhifei Biological Products retained neutralizing activity against the South African variant, their researchers said in a paper.

The paper was written by researchers from Sinopharm-affiliated Beijing Institute of Biological Products, the Institute of Microbiology of Chinese Academy of Sciences, which is co-developing a candidate with Zhifei unit, and two other Chinese agencies.

However, the samples’ activity against the variant was weaker than against the original virus and another variant currently spreading globally, according to the paper published on website BioRxiv ahead its peer-review.

The activity reduction “should be taken into account for its impact for the clinical efficacy of these vaccines,” they said.

The Sinopharm vaccine is approved in China for general public use and is also used in several other countries including the United Arab Emirates (UAE). The Zhifei shot is in late-stage clinical trials in China and overseas. 

Preliminary clinical trial data on vaccines from Novavax Inc and Johnson & Johnson also showed they were significantly less effective at preventing COVID-19 in trial participants in South Africa, where the potent new variant is widespread. — Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Economy

Pag-IBIG Fund has financed 5,411 socialized homes for minimum-wage and low-income members in the first four months of 2022, its top executives said today....

Economy

SRI LANKA’s impending default on $12.6 billion of overseas bonds is flashing a warning sign to investors in other developing nations that surging inflation...

Economy

A WOMAN observes a period calendar tracker app on her mobile phone at her home in Madrid, Spain, May 16. — REUTERS MADRID —...

Economy

WASHINGTON — The US Justice Department on Tuesday sued Steve Wynn, the former CEO of Wynn Resorts, to compel him to register as an...

Economy

WASHINGTON/SEOUL — Despite battling a wave of suspected coronavirus disease 2019 (COVID-19) infections, North Korea appears to be preparing to test an intercontinental ballistic...

Economy

IN MANY PARTS of the world, inflation is climbing quickly, including in the US, where I live and where inflation is now north of...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Economy

Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Investing

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Investing

As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.